Why the study?
Does admission HbA1c level predict angiographic characteristics and short-term clinical outcomes in nondiabetic patients with acute STEMI?
Does admission HbA1c level predict angiographic characteristics and short-term clinical outcomes in nondiabetic patients with acute STEMI?
In nondiabetic patients with acute STEMI, elevated admission HbA1c is a predictor of more severe coronary artery disease and worse short-term clinical outcomes.
Answers are grounded in this paper and cite their sources.
May support HbA1c for risk stratification in nondiabetic STEMI; leaves open whether targeting it alters outcomes.
We aimed to assess the predictive value of admission HbA1c level in nondiabetic patients presented by acute STEMI, on outcome of PCI and short term outcome of adverse cardiac events. Methods. 60 nondiabetic patients were admitted to Cardiology Department, Zagazig University Hospital, with acute STMI: 27 patients with HbA1c levels of 4.5% to 6.4% (group 1), 17 patients with HbA1c levels of 6.5% to 8.5% (group 2), and 16 patients with HbA1c levels higher than 8.5% (group 3). Either invasive intervention was done at admission by (pPCI) or coronary angiography was done within month (3-28 days) from taking thrombolytic. Participants were followed up for 6 months. Results. There was significant difference among different groups of HbA1c as regards the number of diseased vessels, severity of CAD lesions (p value < 0.01), and TIMI flow grades (p value < 0.05). There was significant difference among different groups as regards the adverse cardiac events on short term follow-up period (p value < 0.05). Conclusion. The present study showed that admission higher HbA1c level in patients presented by acute STEMI is associated with more severe CAD, lower rate of complete revascularization, and higher incidence of adverse cardiac events.
No takes yet. Share an insight, caveat, or question.
Elsherbiny et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: